Floatz logo

Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Ipilimumab
Large Cell Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Lung Neuroendocrine Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Lung Sarcomatoid Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Major Salivary Gland Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Malignant Peripheral Nerve Sheath Tumor
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Malignant Testicular Leydig Cell Tumor
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Malignant Sertoli Cell Tumor
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Sex Cord-Stromal Tumor
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Lipid-Cell Variant Infiltrating Bladder Urothelial Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Pituitary Gland Adenoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Prostate Small Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Minimally Invasive Lung Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Carcinosarcoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Mucinous Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Mucinous Cystadenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Nasal Cavity Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Nasal Cavity Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Undifferentiated Carcinoma Of Nasopharynx
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Oral Cavity Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Ovarian Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Ovarian Mucinous Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Ovarian Squamous Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Showing 1526 to 1550 of 3,272 assets
PreviousPage 62 of 131Next